Home › Niet-kleincellige longkanker › Connecticut › New Haven
Niet-kleincellige longkanker klinische studies in New Haven, CT
41 studies voor Niet-kleincellige longkanker zoeken deelnemers op locaties in en rond New Haven (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
RekruterenFase 2
- Yale New Haven Hospital /ID# 271584, New Haven
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruterenFase 3
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · 3 mijl verwijderd
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mijl verwijderd
- en nog 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruterenFase 1/2
- Yale Cancer Center, New Haven
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RekruterenFase 3
- Yale University School of Medicine ( Site 0201), New Haven
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekruterenFase 1
- Exelixis Clinical Site #62, New Haven
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
RekruterenFase 3
- Smilow Cancer Center at Yale-New Haven ( Site 3253), New Haven
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RekruterenFase 2
- Yale Cancer Center, New Haven
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RekruterenFase 1
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Yale - New Haven Hospital - Yale Cancer Center, New Haven
- Smilow Cancer Hospital Phase 1 Unit, New Haven
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
RekruterenFase 1
- Yale Cancer Center, New Haven
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RekruterenFase 3
- Yale University, Smillow Cancer Center, New Haven
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
RekruterenFase 2
- Yale University, New Haven
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RekruterenFase 2
- Yale New Haven Hospital Yale Cancer Center, New Haven
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
RekruterenFase 2
- Research Site, New Haven
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekruterenFase 1
- Yale University, Yale Cancer Center, New Haven
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
RekruterenFase 3
- Research Site, West Haven · 3 mijl verwijderd
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RekruterenFase 1
- Yale Cancer Center, New Haven
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
RekruterenFase 1/2
- Yale University School of Medicine - Yale Cancer Center, New Haven
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
RekruterenFase 1/2
- Yale Cancer Center, New Haven
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
RekruterenFase 2
- Yale Cancer Center, New Haven
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
RekruterenFase 1
- Yale Cancer Center, New Haven
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
RekruterenFase 1/2
- Yale Cancer Center, New Haven
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RekruterenFase 3
- Yale University School of Medicine, New Haven
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RekruterenFase 1
- Yale Cancer Center, New Haven
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
RekruterenFase 1
- Yale Cancer Center, New Haven
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
RekruterenFase 1/2
- Yale University, New Haven
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
RekruterenFase 3
- Research Site, New Haven
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
RekruterenFase 1/2
- Yale University, New Haven
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
RekruterenFase 1/2
- Yale University - Cancer Center, New Haven
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
RekruterenFase 1/2
- Yale New Haven Hospital, Yale Cancer Center, New Haven
Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
RekruterenFase 1/2
- Smilow Cancer Hospital, New Haven
- Smilow Cancer Hospital - Hamden Care Center, Hamden · 6 mijl verwijderd
- Smilow Cancer Hospital Care Center - Guilford, Guilford · 13 mijl verwijderd
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
RekruterenFase 1
- Yale University School of Medicine /ID# 225707, New Haven
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruterenFase 2
- Yale University, New Haven
- Smilow Cancer Hospital-Orange Care Center, Orange · 5 mijl verwijderd
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mijl verwijderd
- en nog 2
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RekruterenFase 1
- Smilow Cancer Hospital (Yale University), New Haven
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RekruterenFase 1
- Yale University, New Haven
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RekruterenFase 2
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mijl verwijderd
- Smilow Cancer Hospital-Derby Care Center, Derby · 8 mijl verwijderd
- en nog 1
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruterenFase 2/3
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mijl verwijderd
- Smilow Cancer Hospital-Derby Care Center, Derby · 8 mijl verwijderd
- en nog 1
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekruterenFase 2
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mijl verwijderd
- Smilow Cancer Hospital-Derby Care Center, Derby · 8 mijl verwijderd
- en nog 1
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
RekruterenFase 2
- Smilow Cancer Hospital at Yale - New Haven, New Haven
- Yale-New Haven Hospital- Yale Cancer Center, New Haven
- Smilow Cancer Hospital Phase 1 Unit, New Haven
- en nog 1
Repositioning Immunotherapy in VetArans With Lung Cancer
RekruterenFase 2
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven · 3 mijl verwijderd
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RekruterenFase 1/2
- Yale University, New Haven
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
RekruterenFase 1/2
- Yale Cancer Center, New Haven
Niet-kleincellige longkanker studies in andere steden
- Houston, TX145 studies
- New York City, NY121 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH57 studies
- Washington, DC55 studies
Andere studies in New Haven
- Borstkanker38 studies
- Kanker (alle vormen)33 studies
- Metastatische kanker23 studies
- Longkanker22 studies
- Plaveiselcelcarcinoom van hoofd en hals22 studies
- Eierstokkanker21 studies
- Colorectale kanker20 studies
- Prostaatkanker20 studies
- Acute myeloïde leukemie17 studies
- Alcoholgebruiksstoornis (AUD)17 studies
- Opioïde-overdosering17 studies
- Aldermeesklierkanker16 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.